Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. Juni 2006 17:00 ET | Quelle: Novartis Pharma AG

Patients with treatment-resistant leukemia achieve high responses to Tasigna® (nilotinib) in first published clinical trial results

New England Journal of Medicine publishes first evaluation of Tasigna, a promising next-generation targeted therapy, five years after issuing historic Glivec® Phase I data Tasigna...
13. Juni 2006 08:30 ET | Quelle: Novartis Pharma AG

Novartis unveils further impressive efficacy data for the investigational oral diabetes compound Galvus® showing significant blood sugar reductions

New data show blood sugar (HbA1c) reduction of up to 2.8% with the combination of Galvus and pioglitazone in type 2 diabetic patients with poor glycemic control Data also show no significant...
13. Juni 2006 01:15 ET | Quelle: Novartis Pharma AG

Rasilez® shows superior efficacy to ACE inhibitor ramipril in head-to-head study involving people with diabetes and high blood pressure

Superior systolic blood pressure reductions with Rasilez monotherapy versus ramipril (ACE inhibitor) seen in study [1] Rasilez shows additive blood pressure reductions when used with ACE...
13. Juni 2006 01:00 ET | Quelle: Novartis Pharma AG

Novartis expands late-stage vaccines pipeline with novel vaccine for prevention of Japanese Encephalitis virus infections

Novartis enters into agreement with Intercell AG to acquire marketing and distribution rights to IC51, a Phase III vaccine for prevention of Japanese Encephalitis virus infections with orphan status...
07. Juni 2006 01:15 ET | Quelle: Novartis Pharma AG

Novartis makes offer for NeuTec Pharma, acquisition adds two highly promising biotech drugs to portfolio for patients with severe infections

Public offer to acquire 100% of UK specialty biopharmaceutical company for GBP 10.50 per share; total equity consideration of GBP 305 million (USD 569 million) Transaction unanimously...
06. Juni 2006 01:15 ET | Quelle: Novartis Pharma AG

Novartis strengthens infectious disease portfolio by acquiring rights to Albuferon(TM), a hepatitis C interferon drug set to enter Phase III trials

Albuferon(TM) a late-stage novel interferon drug in-licensed from Human Genome Sciences (HGS), expands range of Novartis compounds that target hepatitis C Designed to offer a valuable...
04. Juni 2006 17:00 ET | Quelle: Novartis Pharma AG

Novartis launches global program expanding access to investigational compound nilotinib (AMN107) for patients with hard-to-treat leukemia

New worldwide program addresses unmet medical need for patients with treatment-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) Nilotinib receives FDA fast track...
03. Juni 2006 16:00 ET | Quelle: Novartis Pharma AG

Glivec® sets new treatment standard in chronic myeloid leukemia with high overall survival, increasing response and decreasing progression

Nearly 90% of patients with Philadelphia chromosome-positive CML alive at five years with new analysis showing less than 5% mortality due to CML Response rate to Glivec increases substantially...
31. Mai 2006 04:30 ET | Quelle: Novartis Pharma AG

Sandoz gets precedent-setting US approval for Omnitrope® as first follow-on version of a previously approved recombinant biotechnology drug

US approval a breakthrough in goal of making high-quality and cost-effective follow-on biotechnology medicines available for patients Omnitrope now approved for treatment of growth...
23. Mai 2006 04:15 ET | Quelle: Novartis Pharma AG

Novartis lance un projet de recherche innovant sur le paludisme dans le cadre d'un nouveau partenariat public-privé

Le NITD, le Wellcome Trust, l'Economic Development Board de Singapour et Medicines for Malaria Venture (MMV) s'associent dans la recherche sur le paludisme. Ce partenariat vise à...

Vorherige Seite

Nächste Seite